![]() |
市場調查報告書
商品編碼
2149244
生物製藥下游製程市場:規模、佔有率、成長、全球產業分析、區域趨勢及2026年至2034年預測Downstream Processing Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034 |
||||||
2025年全球生物製藥下游製程市場規模為348.4億美元,預計將從2026年的372.6億美元成長至2034年的767.6億美元,預測期內複合年成長率(CAGR)為9.46%。北美將成為全球生物製藥下游製程市場的主要驅動力,預計2025年市佔率將達到42.16%。該市場呈現強勁成長勢頭,主要得益於生物製藥生產的成長、對生物製藥和生物相似藥需求的不斷增加以及先進純化技術的日益普及。
生物製藥下游製程是指在生物製藥生產完成後,用於分離、純化、濃縮和配製產品的技術和系統。這些製程對於將未經純化的生物混合物轉化為高純度、具有治療效果的產品至關重要。隨著單株抗體、重組蛋白、疫苗、細胞和基因療法以及其他先進生物製藥的產量不斷成長,對高效生物製藥下游解決方案的需求也日益旺盛。 2025年11月,Astra Zeneca投資20億美元擴建製造地,顯示該公司持續增加對生物製藥生產能力的投資。
生物製藥下游製程市場的關鍵點
市場規模及預測:預計2025年市場規模為348.4億美元,2026年達372.6億美元,2034年達767.6億美元。 2026年至2034年,市場預計將以9.46%的複合年成長率成長。
市佔率:預計到 2025 年,北美將佔 42.16% 的市佔率。服務業預計將以 11.86% 的複合年成長率成長,而細胞和基因治療製造業預計將以 12.18% 的複合年成長率成長。
各區域主要亮點:預計北美地區2025年將達到146.9億美元;歐洲地區2026年將達99.4億美元;亞太地區2026年將達87.3億美元;美國2026年將達141億美元。
市場動態
市場促進因素:生物製藥和生物相似藥的快速成長正在推動市場需求。
生物製藥和生物相似藥的研發和生產日益成長,是下游製程需求的主要驅動力。這些產品需要經過多道過濾、層析法、純化和病毒去除步驟,才能滿足嚴格的品質和安全要求。隨著生物製藥生產設施的擴張,對生物製藥下游製程所需的設備、耗材和服務的需求也隨之成長。
市場限制因素:先進DSP設備和耗材的營運成本高。
先進的生物製藥下游加工設備、層析法樹脂、過濾系統和耗材的高成本可能給生產商帶來巨大的財務挑戰。複雜的純化要求和嚴格的監管標準會進一步增加生產成本,這可能會限制小規模生物製藥生產商採用這些技術。
市場機會:一次性技術的發展
一次性生物製藥下游製程技術正在創造市場拓展機會。靈活的過濾系統、一次性層析法解決方案、病毒去除模組和自動化技術能夠提高生產柔軟性並降低污染風險。這些技術的應用對於小規模工廠和處理多種產品的工廠尤其重要。
市場挑戰:與連續生物製程過程模式不相容
生物製藥的多個下游製程仍難以整合到完整的連續生產系統中。病毒去活化、離心、沉澱和無菌過濾可能需要大量的緩衝液或分批處理,這給同步和製程整合帶來了挑戰。
生物製藥下游製程市場趨勢
向連續高密度生物製藥下游製程過渡
生物製藥產業正從傳統的批次純化轉向連續和一體化的下游製程。這些方法能夠提高產量、縮短處理時間並增強生產作業的靈活性。自動化和模組化製程平台的重要性也日益凸顯。
生物製藥下游製程市場細分分析。
報價
市場分為產品和服務兩大類。預計到2025年,產品類市場將成為市場成長的主要驅動力,這主要得益於過濾器、層析法樹脂、薄膜和其他耗材的廣泛應用。服務類市場預計在預測期內將以11.86%的複合年成長率成長。
透過技術
該市場涵蓋分離、過濾、濃縮、病毒去活化和緩衝液交換等應用。預計到2025年,過濾將成為市場成長的主要驅動力,到2026年將佔35.0%的市場佔有率,這主要得益於其在下游工作流程中的廣泛應用。
用途別
該市場涵蓋單株抗體和重組蛋白的生產、純化和去病毒處理、疫苗生產、細胞和基因治療產品生產、血液和血漿生產等。預計到2025年,單株抗體和重組蛋白生產將佔最大市場佔有率,到2026年將達到38.4%。細胞和基因治療產品生產預計將以12.18%的複合年成長率成長。
最終用戶
預計到 2025 年,製藥和生技公司將引領市場,到 2026 年將佔 47.5% 的市場。 CMO/CDMO 預計在預測期內將以 11.11% 的複合年成長率成長。
區域展望
北美洲
北美仍然是重要的區域市場,預計到2025年將達到146.9億美元。該地區受益於強大的生物製藥生產生態系統、不斷擴大的合約研發發病(CDMO)活動以及對生產設施的持續投資。美國市場預計到2026年將達到141億美元。
歐洲
預計2026年,歐洲市場規模將達到99.4億美元,年複合成長率為9.10%。英國、德國和法國預計到2026年將分別達到21.4億美元、15.5億美元和13.7億美元。
亞太地區
預計到2026年,亞太地區市場規模將達到87.3億美元,主要受製藥業擴張和生物製藥投資的推動。印度和中國預計到2026年將分別達到16億美元和15.5億美元。由於持續投資於生物製藥生產和加工技術,日本仍然是一個重要的市場。
拉丁美洲
預計到 2026 年,拉丁美洲生物製藥下游市場規模將達到 16.9 億美元。政府和私營部門為提高生物製藥生產能力而採取的措施不斷增加,正在推動該地區的成長。
中東和非洲
預計中東和非洲市場將呈現溫和成長,其中海灣合作理事會(GCC)市場預計到2026年將達到4.9億美元。醫療保健領域的投資增加和藥品生產能力的提高正在為該地區的商業機會提供支持。
The global downstream processing market size was valued at USD 34.84 billion in 2025 and is projected to grow from USD 37.26 billion in 2026 to USD 76.76 billion by 2034, exhibiting a CAGR of 9.46% during the forecast period. North America dominated the global downstream processing market with a 42.16% market share in 2025. The market is witnessing strong growth due to increasing biopharmaceutical manufacturing, rising demand for biologics and biosimilars, and growing adoption of advanced purification technologies.
Downstream processing comprises technologies and systems used to separate, purify, concentrate, and formulate biological products after production. These processes are essential for converting crude biological mixtures into high-purity and therapeutically active products. Increasing production of monoclonal antibodies, recombinant proteins, vaccines, cell and gene therapies, and other advanced biologics is generating demand for efficient downstream processing solutions. In November 2025, AstraZeneca invested USD 2.0 billion to expand its manufacturing footprint in Maryland, demonstrating continued investment in biopharmaceutical manufacturing capacity.
DOWNSTREAM PROCESSING MARKET KEY TAKEAWAYS
Market Size & Forecast: The market was valued at USD 34.84 billion in 2025, is projected to reach USD 37.26 billion in 2026, and is expected to reach USD 76.76 billion by 2034. The market is expected to expand at a 9.46% CAGR from 2026 to 2034.
Market Share: North America accounted for 42.16% in 2025. The services segment is expected to grow at a 11.86% CAGR, while cell and gene therapy production is expected to grow at a 12.18% CAGR.
Key Regional Highlights: North America reached USD 14.69 billion in 2025. Europe is projected to reach USD 9.94 billion in 2026, while Asia Pacific is projected to reach USD 8.73 billion in 2026. The U.S. is projected to reach USD 14.10 billion in 2026.
MARKET DYNAMICS
MARKET DRIVERS: Exponential Growth of Biologics and Biosimilars Augments Market Demand
The increasing development and manufacturing of biologics and biosimilars is a major factor driving demand for downstream processing. These products require multiple filtration, chromatography, purification, and viral clearance steps to meet stringent quality and safety requirements. Expanding biopharmaceutical manufacturing facilities is therefore increasing demand for downstream processing equipment, consumables, and services.
MARKET RESTRAINTS: High Operational Costs of Advanced DSP Equipment and Consumables
High costs associated with advanced downstream processing equipment, chromatography resins, filtration systems, and consumables can create financial challenges for manufacturers. Complex purification requirements and stringent regulatory standards can further increase production expenses, potentially limiting adoption among smaller biopharmaceutical manufacturers.
MARKET OPPORTUNITIES: Advances in Single-Use Technologies
Single-use downstream processing technologies are creating opportunities for market expansion. Flexible filtration systems, single-use chromatography solutions, viral clearance modules, and automation technologies can provide manufacturing flexibility and reduce contamination risks. Their adoption is particularly relevant for smaller and multi-product facilities.
MARKET CHALLENGES: Incompatibility with Continuous Bioprocessing Models
Several downstream operations remain difficult to integrate into fully continuous manufacturing systems. Viral inactivation, centrifugation, precipitation, and sterilizing filtration can require large buffer volumes or batch-oriented operations, creating synchronization and process-integration challenges.
DOWNSTREAM PROCESSING MARKET TRENDS
Shift toward Continuous and Intensified Downstream Processing
The industry is increasingly moving from conventional batch purification toward continuous and intensified downstream processing. These approaches can improve throughput, reduce processing time, and support more flexible manufacturing operations. Automation and modular processing platforms are also becoming increasingly important.
DOWNSTREAM PROCESSING MARKET SEGMENTATION ANALYSIS
By Offering
The market is divided into products and services. The products segment dominated in 2025, supported by extensive use of filters, chromatography resins, membranes, and other consumables. The services segment is expected to register a 11.86% CAGR during the forecast period.
By Technique
The market includes separation, filtration, concentration, viral inactivation, buffer exchange, and others. Filtration dominated in 2025 and is projected to hold a 35.0% share in 2026, driven by its extensive application across downstream workflows.
By Application
The market covers mAb and recombinant protein production, polishing and viral clearance, vaccine production, cell and gene therapy production, blood and plasma production, and others. mAb and recombinant protein production dominated in 2025 and is projected to account for 38.4% in 2026. Cell and gene therapy production is expected to grow at a 12.18% CAGR.
By End User
Pharmaceutical and biotechnology companies dominated in 2025 and are expected to hold a 47.5% share in 2026. CMOs/CDMOs are expected to grow at a 11.11% CAGR during the forecast period.
DOWNSTREAM PROCESSING MARKET REGIONAL OUTLOOK
NORTH AMERICA
North America remained the leading regional market, reaching USD 14.69 billion in 2025. The region benefits from a strong biopharmaceutical manufacturing ecosystem, expanding CDMO activities, and continued investment in production facilities. The U.S. market is projected to reach USD 14.10 billion in 2026.
EUROPE
Europe is projected to reach USD 9.94 billion in 2026, growing at a 9.10% CAGR. The U.K., Germany, and France are expected to reach USD 2.14 billion, USD 1.55 billion, and USD 1.37 billion, respectively, in 2026.
ASIA PACIFIC
Asia Pacific is projected to reach USD 8.73 billion in 2026, supported by increasing pharmaceutical manufacturing and investment in biologics. India and China are each estimated to reach USD 1.60 billion and USD 1.55 billion, respectively, in 2026. Japan remains an important market due to ongoing investment in biopharmaceutical manufacturing and processing technologies.
LATIN AMERICA
The Latin America downstream processing market is projected to reach USD 1.69 billion in 2026. Increasing government and private-sector initiatives aimed at improving biologics manufacturing capabilities are supporting regional development.
MIDDLE EAST & AFRICA
The Middle East & Africa market is expected to witness moderate growth, with the GCC market projected to reach USD 0.49 billion in 2026. Increasing healthcare investment and development of pharmaceutical manufacturing capabilities are supporting regional opportunities.
COMPETITIVE LANDSCAPE
Key Industry Players: Strategic Collaborations and Acquisitions
The global downstream processing market has a semi-consolidated competitive structure. Key companies are focusing on product launches, acquisitions, capacity expansion, technology development, and strategic collaborations. Major participants include Sartorius AG, Repligen Corporation, Merck KGaA, Danaher, METTLER TOLEDO, Thermo Fisher Scientific Inc., Waters Corporation, ALFA LAVAL, PHYTON LTD, and WuXi Biologics.
KEY INDUSTRY DEVELOPMENTS
January 2025: Bio-Rad Laboratories launched Nuvia wPrime 2A Media for biomolecule purification.
November 2025: Enquyst Technologies showcased a chromatography-free downstream processing platform for monoclonal antibodies.
December 2024: Repligen Corporation launched AVIPure dsRNA Clear OPUS columns for mRNA therapeutics and vaccines.
September 2024: Sartorius AG launched Vivaflow Tangential Flow Filtration Cassettes for laboratory downstream processes.
November 2022: Alfa Laval launched a cross-flow skid-mounted membrane filtration system supporting upstream and downstream applications.
REPORT COVERAGE
The global downstream processing market report covers market size and forecast data for 2025, 2026, and 2034, along with segmentation by offering, technique, application, end user, and geography. The report includes market dynamics, trends, technological developments, product launches, mergers and acquisitions, regional analysis, competitive developments, and profiles of major industry participants.
CONCLUSION
The global downstream processing market is projected to expand from USD 34.84 billion in 2025 to USD 37.26 billion in 2026 and USD 76.76 billion by 2034. Increasing biologics and biosimilars production, expanding biopharmaceutical manufacturing capacity, rising adoption of single-use technologies, and advancements in continuous and intensified processing are key factors supporting market development. North America remains the leading regional market, while Europe and Asia Pacific are expected to provide substantial opportunities through expanding biologics manufacturing and investments in advanced downstream processing technologies.
Segmentation By Offering, Technique, Application, End User, and Region
By Offering
By Technique
By Application
By End User
By Region